EP12.01. An Observational Study Analyzing Progression Free Survival of Patients With EGFR Mutant NSCLC Treated with Osimertinib in South Carolina - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Michael Pavy
Meta Tag
Speaker Michael Pavy
Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2
progression-free survival
EGFR mutant non-small cell lung cancer
epidermal growth factor receptor tyrosine kinase inhibitor
EGFR activating mutations
exon mutations
programmed death ligand mutations
retrospective observational study
South Carolina
Powered By